[Asia Economy Reporter Oh Ju-yeon] Despite expectations that the stock market, which had risen sharply since March, might take a breather this month by gradually focusing on fundamentals (corporate earnings), the KOSPI and KOSDAQ indices maintained a solid trend on the 2nd. The KOSPI fluctuated around the 2120 level but continued its upward momentum compared to the previous day, while the KOSDAQ index rose by over 1%, led by strong performances in pharmaceutical and bio stocks.
As of 10:47 a.m. that day, the KOSPI stood at 2121.57, up 0.71% from the previous trading day. The KOSPI opened at 2116.72, a 0.48% increase from the previous day, and rose as high as 2126.33 during the session.
By investor type, individuals and institutions net bought 20 billion KRW and 116.1 billion KRW respectively, while foreigners net sold 144.5 billion KRW.
Among the top market capitalization stocks, Samsung Electronics traded at 52,500 KRW, down 0.19% from the previous day, and SK Hynix traded at 84,300 KRW, down 0.17%. Samsung Biologics and Celltrion showed strong gains, rising 4.12% and 3.87% respectively.
Notably, SK Biopharm was listed on the KOSPI market that day, drawing intense investor interest by achieving the so-called 'ttasang'?opening at twice the IPO price and then hitting the daily upper limit. SK Biopharm’s opening price was 98,000 KRW, double the IPO price of 49,000 KRW. Shortly after the market opened, it hit the upper limit price of 127,000 KRW.
In the KOSDAQ market, pharmaceutical and bio-related stocks continued their strong performance.
The KOSDAQ index closed at 735.55, up 1.10% from the previous trading day. Among the top market capitalization stocks, Celltrion Healthcare traded at 109,800 KRW, up 4.67%, and Celltrion Pharm rose 2.31%.
By investor type, individuals and institutions net sold 23.3 billion KRW and 5 billion KRW respectively, while foreigners net bought 28.2 billion KRW.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
